Novo Nordisk A/SOMXCOP: NOVO_B

Novo Nordisk A/S: IT Security incident at Novo Nordisk

· Issued by Novo Nordisk A/S

Summary by 6ix AI

Novo Nordisk A/S, a healthcare company headquartered in Denmark, said on 11 June 2026 that it has identified an IT security incident involving unauthorised access to a limited number of internal IT systems. It found that certain non-public data, including personal data, were copied externally without authorisation.

Key details

  • Novo Nordisk A/S launched an investigation with the help of external cybersecurity experts and is in contact with the relevant authorities.
  • As part of its response, the company took certain internal IT systems offline temporarily, among other security measures.
  • Novo Nordisk A/S says its core business operations are not impacted and remain up and running.
  • The company is informing the impacted parties as appropriate.

What’s still pending

  • The investigation and response are ongoing.
  • The company is working to bring the affected systems back online in a controlled and safe manner and says this process takes time.

6ix AI wrote this summary from the release below and checked it against the release.

Bagsværd, Denmark, 11 June 2026 – Novo Nordisk A/S has identified an IT security incident involving unauthorised access to a limited number of internal IT systems. Upon learning of the incident, we launched an investigation with the assistance of external cybersecurity experts, and we are in contact with the relevant authorities.

As part of our response, multiple security measures have been taken, including temporarily taking certain internal IT systems offline to protect our environment. We are working to bring the affected systems back online in a controlled and safe manner; however, we acknowledge this process takes time.

Our core business operations are not impacted and remain up and running.

While our investigation and response are ongoing, we have discovered that certain non-public data, including personal data, were copied externally without authorisation. We are informing the impacted parties as appropriate.

Protecting the security and integrity of our systems and delivering reliable products and support to patients remain our highest priorities.

For more information about this incident, including privacy notifications, go to novonordisk.com.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Novo Nordisk Media:

Ambre James-Brown
+45 3079 9289
[email protected]

Liz Skrbkova (US)
+1 609 917 0632
[email protected]

Novo Nordisk Investors:

Michael Novod
+45 3075 6050
[email protected]

Jacob Martin Wiborg Rode
+45 3075 5956
[email protected]

Sina Meyer
+45 3079 6656
[email protected]

Max Ung
+45 3077 6414
[email protected]

Christoffer Sho Togo Tullin
+45 3079 1471
[email protected]

Alex Bruce
+45 3444 2613
[email protected]

Mads Berner Bruun
+45 3075 2936
[email protected]

Frederik Taylor Pitter (US)
+1 609 613 0568
[email protected]

Attachment

Novo Nordisk A/S on 6ix

Earlier from Novo Nordisk

Later from Novo Nordisk

All Novo Nordisk news releases